Reduced intensity and non-myeloablative allogenic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin's lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy
Gauthier, J; Castagna, L; Garnier, Fet al.
2017 • In Bone Marrow Transplantation, 52, p. 689-696
[en] Allogeneic stem cell transplantation (allo-SCT) following a non-myeloablative (NMA) or reduced-intensity conditioning (RIC) is considered a valid approach to treat patients with refractory/relapsed Hodgkin lymphoma (HL). When an HLA-matched donor is lacking a graft from a familial haploidentical (HAPLO) donor, a mismatched unrelated donor (MMUD) or cord blood (CB) might be considered. In this retrospective study, we compared the outcome of patients with HL undergoing a RIC or NMA allo-SCT from HAPLO, MMUD or CB. Ninety-eight patients were included. Median follow-up was 31 months for the whole cohort. All patients in the HAPLO group (N = 34) received a T-cell replete allo-SCT after a NMA (FLU-CY-TBI, N = 31, 91%) or a RIC (N = 3, 9%) followed by post-transplant cyclophosphamide. After adjustment for significant covariates, MMUD and CB were associated with significantly lower GvHD-free relapse-free survival (GRFS; hazard ratio (HR) = 2.02, P = 0.03 and HR = 2.43, P = 0.009, respectively) compared with
HAPLO donors. In conclusion, higher GRFS was observed in Hodgkin lymphoma patients receiving a RIC or NMA allo-SCT with posttransplant cyclophosphamide from HAPLO donors. Our findings suggest they should be favoured over MMUD and CB in this setting.
Disciplines :
Hematology
Author, co-author :
Gauthier, J
Castagna, L
Garnier, F
Guillaume, T
Socié, G
Maury, S
Maillard, N
Tabrizi, R
Marchand, T
Malfuson, J-V
Gac, A-C
Gyan, E
Mercier, M
BEGUIN, Yves ; Centre Hospitalier Universitaire de Liège - CHU > Service d'hématologie clinique
Reduced intensity and non-myeloablative allogenic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin's lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy
Copelan, E.A., Hematopoietic stem-cell transplantation (2006) N Engl J Med, 354, pp. 1813-1826
Armand, P., Gibson, C.J., Cutler, C., Ho, V.T., Koreth, J., Alyea, E.P., A disease risk index for patients undergoing allogeneic stem cell transplantation (2012) Blood, 120, pp. 905-913
Armand, P., Kim, H.T., Logan, B.R., Wang, Z., Alyea, E.P., Kalaycio, M.E., Validation and refinement of the disease risk index for allogeneic stem cell transplantation (2014) Blood, 123, pp. 3664-3671
Bonnet, D., Warren, E.H., Greenberg, P.D., Dick, J.E., Riddell, S.R., CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells (1999) Proc Natl Acad Sci USA, 96, pp. 8639-8644
Bleakley, M., Riddell, S.R., Molecules and mechanisms of the graft-versusleukaemia effect (2004) Nat Rev Cancer, 4, pp. 371-380
Barrett, A.J., Malkovska, V., Graft-versus-leukaemia: Understanding and using the alloimmune response to treat haematological malignancies (1996) Br J Haematol, 93, pp. 754-761
Welniak, L.A., Blazar, B.R., Murphy, W.J., Immunobiology of allogeneic hematopoietic stem cell transplantation (2007) Annu Rev Immunol, 25, pp. 139-170
Beauverd, Y., Roosnek, E., Tirefort, Y., Nagy-Hulliger, M., Bernimoulin, M., Tsopra, O., Validation of the disease risk index for outcome of patients undergoing allogeneic hematopoietic stem cell transplantation after T cell depletion (2014) Biol Blood Marrow Transplant, 20, pp. 1322-1328
Chalandon, Y., Roosnek, E., Mermillod, B., Waelchli, L., Helg, C., Chapuis, B., Can only partial T-cell depletion of the graft before hematopoietic stem cell transplantation mitigate graft-versus-host disease while preserving a graft-versus-leukemia reaction? A prospective phase II study (2006) Biol Blood Marrow Transplant, 12, pp. 102-110
Chakrabarti, S., MacDonald, D., Hale, G., Holder, K., Turner, V., Czarnecka, H., T-cell depletion with Campath-1H 'in the bag' for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival (2003) Br J Haematol, 121, pp. 109-118
Armand, P., Deeg, H.J., Kim, H.T., Lee, H., Armistead, P., De Lima, M., Multicenter validation study of a transplantation-specific cytogenetics grouping scheme for patients with myelodysplastic syndromes (2010) Bone Marrow Transplant, 45, pp. 877-885
Armand, P., Kim, H.T., Zhang, M.J., Perez, W.S., Dal Cin, P.S., Klumpp, T.R., Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: A center for international blood and marrow transplant research study (2012) Biol Blood Marrow Transplant, 18, pp. 280-288
Kaplan, E.L., Meier, P., Nonparametric estimation from incomplete observations (1958) J Am Stat Assoc, 53, pp. 457-481
Fine, J., Gray, R., A proportional hazards model for the subdistribution of a competing risk (1999) J Am Stat Assoc, 94, pp. 496-509
Sorror, M.L., Maris, M.B., Storb, R., Baron, F., Sandmaier, B.M., Maloney, D.G., Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT (2005) Blood, 106, pp. 2912-2919
Gratwohl, A., Stern, M., Brand, R., Apperley, J., Baldomero, H., De Witte, T., Risk score for outcome after allogeneic hematopoietic stem cell transplantation: A retrospective analysis (2009) Cancer, 115, pp. 4715-4726
Lee, S.J., Klein, J.P., Barrett, A.J., Ringden, O., Antin, J.H., Cahn, J.Y., Severity of chronic graft-versus-host disease: Association with treatment-related mortality and relapse (2002) Blood, 100, pp. 406-414
Levrat, E., Roosnek, E., Masouridi, S., Mohty, B., Ansari, M., Villard, J., Very long term stability of mixed chimerism after allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies (2015) Bone Marrow Res, 2015, p. 176526
Sorror, M., Storer, B., Sandmaier, B.M., Maloney, D.G., Chauncey, T.R., Langston, A., Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation (2008) Cancer, 112, pp. 1992-2001
Remberger, M., Ackefors, M., Berglund, S., Blennow, O., Dahllof, G., Dlugosz, A., Improved survival after allogeneic hematopoietic stem cell transplantation in recent years a single-center study (2011) Biol Blood Marrow Transplant, 17, pp. 1688-1697
Hahn, T., McCarthy, P.L., Jr., Hassebroek, A., Bredeson, C., Gajewski, J.L., Hale, G.A., Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors (2013) J Clin Oncol, 31, pp. 2437-2449
